BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johansson A, Löfberg C. Novel MCH 1 receptor antagonists: a patent review. Expert Opinion on Therapeutic Patents 2014;25:193-207. [DOI: 10.1517/13543776.2014.993382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Potter LE, Burgess CR. The melanin-concentrating hormone system as a target for the treatment of sleep disorders. Front Neurosci 2022;16:952275. [DOI: 10.3389/fnins.2022.952275] [Reference Citation Analysis]
2 Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol 2020;11:554961. [PMID: 33776749 DOI: 10.3389/fphar.2020.554961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
3 Boutin JA, Tartar AL, van Dorsselaer A, Vaudry H. General lack of structural characterization of chemically synthesized long peptides. Protein Sci 2019;28:857-67. [PMID: 30851143 DOI: 10.1002/pro.3601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pérez-Morales M, Hurtado-Alvarado G, Morales-Hernández I, Gómez-González B, Domínguez-Salazar E, Velázquez-Moctezuma J. Postnatal overnutrition alters the orexigenic effects of melanin-concentrating hormone (MCH) and reduces MCHR1 hypothalamic expression on spontaneous feeding and fasting. Pharmacol Biochem Behav 2018;175:53-61. [PMID: 30196088 DOI: 10.1016/j.pbb.2018.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kawata Y, Okuda S, Hotta N, Igawa H, Takahashi M, Ikoma M, Kasai S, Ando A, Satomi Y, Nishida M, Nakayama M, Yamamoto S, Nagisa Y, Takekawa S. A novel and selective melanin-concentrating hormone receptor 1 antagonist ameliorates obesity and hepatic steatosis in diet-induced obese rodent models. Eur J Pharmacol 2017;796:45-53. [PMID: 27986627 DOI: 10.1016/j.ejphar.2016.12.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
6 Ahmad S, Washburn WN, Hernandez AS, Bisaha S, Ngu K, Wang W, Pelleymounter MA, Longhi D, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Zhang H, Gemzik B, Janovitz EB, Huang C, Zhang L, Robl JA, Murphy BJ. Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2- d ]pyrimidin-4(3 H )-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor. J Med Chem 2016;59:8848-58. [DOI: 10.1021/acs.jmedchem.6b00676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Johansson A. Evolution of physicochemical properties of melanin concentrating hormone receptor 1 (MCHr1) antagonists. Bioorg Med Chem Lett 2016;26:4559-64. [PMID: 27595423 DOI: 10.1016/j.bmcl.2016.08.072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ploj K, Benthem L, Kakol-Palm D, Gennemark P, Andersson L, Bjursell M, Börjesson J, Kärrberg L, Månsson M, Antonsson M, Johansson A, Iverson S, Carlsson B, Turnbull A, Lindén D. Effects of a novel potent melanin-concentrating hormone receptor 1 antagonist, AZD1979, on body weight homeostasis in mice and dogs. Br J Pharmacol 2016;173:2739-51. [PMID: 27400775 DOI: 10.1111/bph.13548] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
9 Igawa H, Takahashi M, Ikoma M, Kaku H, Kakegawa K, Kina A, Aida J, Okuda S, Kawata Y, Noguchi T, Hotta N, Yamamoto S, Nakayama M, Nagisa Y, Kasai S, Maekawa T. Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test. Bioorganic & Medicinal Chemistry 2016;24:2504-18. [DOI: 10.1016/j.bmc.2016.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
10 Igawa H, Takahashi M, Shirasaki M, Kakegawa K, Kina A, Ikoma M, Aida J, Yasuma T, Okuda S, Kawata Y, Noguchi T, Yamamoto S, Fujioka Y, Kundu M, Khamrai U, Nakayama M, Nagisa Y, Kasai S, Maekawa T. Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition. Bioorganic & Medicinal Chemistry 2016;24:2486-503. [DOI: 10.1016/j.bmc.2016.04.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Johansson A, Löfberg C, Antonsson M, von Unge S, Hayes MA, Judkins R, Ploj K, Benthem L, Lindén D, Brodin P, Wennerberg M, Fredenwall M, Li L, Persson J, Bergman R, Pettersen A, Gennemark P, Hogner A. Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties. J Med Chem 2016;59:2497-511. [PMID: 26741166 DOI: 10.1021/acs.jmedchem.5b01654] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
12 Karlsson S, Bergman R, Löfberg C, Moore PR, Pontén F, Tholander J, Sörensen H. Development of a Large-Scale Route to an MCH 1 Receptor Antagonist: Investigation of a Staudinger Ketene–Imine Cycloaddition in Batch and Flow Mode. Org Process Res Dev 2015;19:2067-74. [DOI: 10.1021/acs.oprd.5b00319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
13 Devasthale P, Wang W, Mignone J, Renduchintala K, Radhakrishnan S, Dhanapal J, Selvaraj J, Kuppusamy R, Pelleymounter MA, Longhi D, Huang N, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Huang C, Zhang L, Freeden C, Murphy BJ, Robl JA, Washburn WN. Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies. Bioorganic & Medicinal Chemistry Letters 2015;25:4412-8. [DOI: 10.1016/j.bmcl.2015.09.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
14 Devasthale P, Wang W, Hernandez AS, Moore F, Renduchintala K, Sridhar R, Pelleymounter MA, Longhi D, Huang N, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Huang C, Zhang L, Freeden C, Li Y, Murphy BJ, Robl JA, Washburn WN. Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup. Bioorganic & Medicinal Chemistry Letters 2015;25:2793-9. [DOI: 10.1016/j.bmcl.2015.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]